Should I abruptly discontinue dextroamphetamine (30 mg twice daily, total 60 mg/day) in a 21‑year‑old woman presenting with an acute manic episode instead of tapering it?

Abrupt Discontinuation of Dextroamphetamine in Acute Mania

Yes, you should stop dextroamphetamine abruptly at 60 mg/day in this acute manic episode—tapering is not necessary and may prolong exposure to a drug that is likely worsening her mania.

Rationale for Immediate Discontinuation

Dextroamphetamine is a known trigger for drug-induced mania and must be stopped immediately when acute mania presents. 1

• Sympathomimetic drugs including amphetamines are documented to induce manic episodes, and management involves discontinuation of the suspected drug if medically possible. 1
• The FDA label confirms that withdrawal from dextroamphetamine produces dysphoric mood, depression, fatigue, vivid dreams, insomnia or hypersomnia, increased appetite, and psychomotor changes—but not life-threatening medical complications like seizures or delirium. 2
• Unlike benzodiazepines, where abrupt cessation can cause seizures and death 3, stimulant withdrawal is uncomfortable but medically safe. 2

Why Tapering Is Not Required

The pharmacology of stimulants differs fundamentally from drugs that require tapering.

• Atomoxetine (another noradrenergic ADHD medication) can be discontinued abruptly without tapering, with no discontinuation syndrome or symptom rebound in controlled trials. 4
• Dextroamphetamine withdrawal symptoms are self-limited and resolve without medical intervention; they do not escalate to dangerous physiological states. 2
• Continuing even a reduced dose of dextroamphetamine during a manic episode perpetuates the pharmacologic trigger for mania. 1

Managing Withdrawal Symptoms

Expect and treat withdrawal symptoms supportively, but do not mistake them for a reason to continue the drug.

• Anticipated withdrawal symptoms include fatigue, hypersomnia, increased appetite, and dysphoria lasting days to weeks. 2
• These symptoms will overlap with—but are distinct from—the manic episode itself, which requires antipsychotic or mood-stabilizer treatment. 1
• Do not use benzodiazepines prophylactically for anticipated withdrawal anxiety, as this creates new dependence risk without pharmacologic benefit. 5

Contrast with Benzodiazepine Management

If this patient were also taking benzodiazepines, those would require gradual tapering—but stimulants do not.

• Benzodiazepine withdrawal carries higher risk than opioid withdrawal and must always be conducted gradually, with abrupt cessation potentially causing seizures and death. 3
• When both opioids and benzodiazepines need discontinuation, benzodiazepines are tapered first due to higher withdrawal risks. 3
• Stimulants lack the GABA-mediated neuroadaptation that makes benzodiazepine withdrawal dangerous. 2

Monitoring After Discontinuation

Follow the patient closely for both withdrawal symptoms and evolution of the manic episode.

• Assess daily for the first week for withdrawal fatigue, hypersomnia, and mood changes distinct from mania. 2
• Monitor manic symptoms (elevated mood, decreased need for sleep, pressured speech, impulsivity) which should begin to plateau or improve once the pharmacologic trigger is removed. 1
• Initiate or optimize antimanic treatment (antipsychotic or mood stabilizer) immediately upon stopping dextroamphetamine. 1

Common Pitfall to Avoid

Do not confuse stimulant withdrawal dysphoria with worsening depression requiring antidepressant escalation.

• Withdrawal-related mood symptoms are transient and self-limited, typically resolving within 1–2 weeks. 2
• Premature addition of antidepressants during acute mania or early recovery can re-trigger manic symptoms. 1